lidocaine; tetracaine · Crescita Therap · NDA 021717
Pliaglis
Earliest generic entry, as listed
14 Jan 2031
Blocked by patent: US 10350180, US 10603293, US 10751305, US 12558328.
Listed patents · 4 unexpired
| Patent | Claims | Expires |
|---|---|---|
| US 10350180 | drug product · sets the listed date | 14 Jan 2031 |
| US 10603293 | drug product · sets the listed date | 14 Jan 2031 |
| US 10751305 | drug product · sets the listed date | 14 Jan 2031 |
| US 12558328 | use U-4421 · sets the listed date | 14 Jan 2031 |
Exclusivities · 0 unexpired
No unexpired exclusivities listed.
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.
Products covered · 1
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 021717 · 001 · RLD | cream, topical | 7%;7% | 14 Jan 2031 |